نتایج جستجو برای: intravitreal vegf inhibitor agent

تعداد نتایج: 480981  

Journal: :Drugs of today 2012
E A Verner-Cole S J Davis A K Lauer

Age-related macular degeneration (AMD) can have devastating effects on vision, especially in its neovascular form. In the last decade, the use of intravitreal pharmacotherapy targeted to vascular endothelial growth factor (VEGF) has significantly improved the visual outcomes in patients with neovascular AMD. Although we have become accustomed to these unprecedented improvement outcomes, maintai...

2015

Intravitreal injection of anti-VEGF drugs currently represents the standard of treatment for exudative age-related macular degeneration. Several therapeutic options including steroids, inhibitors of complement factors, anti-platelet-derived growth factor agents, new anti-VEGF drugs, designed ankyrin repeat proteins, sustained drug delivery devices as an alternative to intravitreal injections an...

Journal: :iranian journal of immunology 0
mansour rahimi department of ophthalmology and poostchi eye research center, shiraz university of medical sciences, shiraz, iran seyed sahabaldin shahrzad department of ophthalmology and poostchi eye research center, shiraz university of medical sciences, shiraz, iran mohammad banifatemi department of ophthalmology and poostchi eye research center, shiraz university of medical sciences, shiraz, iran

background: cystoid macular edema (cme) is one of the most common and sight threatening complications of uveitis. intravitreal injection of corticosteroids and anti-vegf antibody are two routine options for treatment. objective: to compare the effects of intravitreal injections of bevacizumab and triamcinolone acetonide for the treatment of persistent macular edema in non-infectious uveitis. me...

Journal: :The Journal of clinical investigation 2008
Lea Scheppke Edith Aguilar Ray F Gariano Ruth Jacobson John Hood John Doukas Jon Cao Glenn Noronha Shiyin Yee Sara Weis Michael B Martin Richard Soll David A Cheresh Martin Friedlander

Retinal and choroidal vascular diseases, with their associated abnormalities in vascular permeability, account for the majority of patients with vision loss in industrialized nations. VEGF is upregulated in ischemic retinopathies such as diabetes and is known to dramatically alter vascular permeability in a number of nonocular tissues via Src kinase-regulated signaling pathways. VEGF antagonist...

2014
Bojie Hu Yan Zhang Qing Zeng Qian Han Lijuan Zhang Mian Liu Xiaorong Li

Therapeutic modalities targeting vascular endothelial growth factor (VEGF) have been used to treat neovascularization and macular edema. However, anti-VEGF treatment alone may cause up-regulation of connective tissue growth factor (CTGF) in the retina, increasing the risk of fibrosis and tractional retinal detachment. Therefore, in this study, we employ a novel dual-target intervention that inv...

Objective(s): To investigate the effect of miR-103 on the angiogenesis of ischemic stroke rats via targeting vascular endothelial growth factor (VEGF) at the molecular level. Materials and Methods: Rat models had received the middle cerebral artery occlusion (MCAO) or sham operation before grouping, and cell models of oxygen-glucose deprivation (OGD) were performed. FITC-dextran, matrigel, and ...

ژورنال: دانشور پزشکی 2019
Amiri, Mona , Ardebili, Mehrdad Eftekhar, Baluchnejadmojarad, Tourandokht , Mehrabi, Jila ,

Background and Objective: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, in which cortical and hippocampus neurons death is the main target of neurodegeneration. In addition to extracellular beta amyloid accumulation and the production of neural tangles, one of effective factors in the pathology of Alzheimer's disease is vascular injury in the elderly including disturbanc...

2014
Paul Hahn

Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy in vitrectomized eyes remains a challenge due to the reduced half-life of these agents. Aflibercept may have stronger binding activity and a longer intravitreal half-life compared to bevacizumab and ranibizumab, but its use in postvitrectomy eyes has not been reported. We present a case of an 89-year-old female, with re...

Journal: :Archives of ophthalmology 2002
Magdalena G Krzystolik Mehran A Afshari Anthony P Adamis Jacques Gaudreault Evangelos S Gragoudas Norman A Michaud Wenjun Li Edward Connolly Charles A O'Neill Joan W Miller

OBJECTIVE To evaluate the safety and efficacy of intravitreal injections of an antigen-binding fragment of a recombinant humanized monoclonal antibody directed toward vascular endothelial growth factor (rhuFab VEGF) in a monkey model of choroidal neovascularization (CNV). METHODS In phase 1 of the study, each animal received intravitreal injections, 500 microg per eye, of rhuFab VEGF in one e...

2016
Jörg T Regula Peter Lundh von Leithner Richard Foxton Veluchamy A Barathi Chui Ming Gemmy Cheung Sai Bo Bo Tun Yeo Sia Wey Daiju Iwata Miroslav Dostalek Jörg Moelleken Kay G Stubenrauch Everson Nogoceke Gabriella Widmer Pamela Strassburger Michael J Koss Christian Klein David T Shima Guido Hartmann

Anti-angiogenic therapies using biological molecules that neutralize vascular endothelial growth factor-A (VEGF-A) have revolutionized treatment of retinal vascular diseases including age-related macular degeneration (AMD). This study reports preclinical assessment of a strategy to enhance anti-VEGF-A monotherapy efficacy by targeting both VEGF-A and angiopoietin-2 (ANG-2), a factor strongly up...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید